Genmab — December 2014
-
http://finance.yahoo.com/news/amgen-onyx-announce-detailed-results-160000281.html Et link alle kan komme på. Se specielt safety 7-8% døde under eller lige efter behandling.
-
Siger hun til sidst at 100% af patienterne med Pomalyst respondere på behandling. Altså100% ORR ?
-
Nej det hun siger er vidst at frontline patienterne i studiet responderer 100% og 50% af patienterne med pomalyst (R/R patienter)
-
Her er en lille Amgen video http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1995470
-
In the KRd and Rd groups, 14 percent versus 4.3 percent of patients achieved a stringent complete response, a measurement indicating superior depth of response... dette syntes jeg da ikke er fantastisk. Dog svært vide hvad de karakteriserer som stringent CR
-
-
In a phase Ib study among patients with newly diagnosed, relapsed or refractory multiple myeloma (MM) the combination of daratumumab with standard treatments was well tolerated and resulted in high rates of response. Results on efficacy and safety of the ongoing trial were presented at the ASH Annual Meeting in San Francisco.
-
“This is a very new and exciting concept in multiple myeloma, as we are seeing that combining this precision approach with the standard of care is leading to more effective treatment without increased toxicity,” said lead study author Philippe Moreau, MD, of University Hospital of Nantes in France.
-
starter den ikke først 21.00 dansk tid ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind